Research and Developments

Page 2 of 2012345...1020...Last »

May 23, 2017

Summary of Research and Developments–2017

Posted in: Daily Living, Latest News, Low Vision Rehabilitation, Research and Developments, Therapies, Treatments, and Procedures

Presentation to the International Low Vision Support Group June 1, 2017 Dan Roberts INTRODUCTION This is my 12th annual summary of leading research and developments occuring during the past 12 months in the fields of blindness and low vision. Sources for further information will appear beneath each topic heading, but for the sake of brevity,
read more »

April 24, 2017

Annual Eye Exams For Retinopathy May Be Unnecessary For Some Type 1 Diabetics

Posted in: Latest News, Research and Developments

Currently, patients who have had type 1 diabetes for 5 years are encouraged to have annual dilated retinal exams to look for possible progression to diabetic retinopathy (DR) or diabetic macular edema (DME). Both of these conditions can lead to severe vision loss and should be treated immediately. Now, a 30-year study* published in April
read more »

April 17, 2017

FDA Approves Lucentis® for Diabetic Retinopathy

Posted in: Latest News, Research and Developments

Genentech, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 and affects
read more »

April 15, 2017

New Sustained Delivery Method for Lucentis

Posted in: Latest News, Research and Developments

Genentech, Inc. is testing a less-invasive method of delivery of their anti-VEGF drug Lucentis into the eyes of patients with wet AMD. Currently, anti-VEGF treatments require regular monthly or bi-monthly injections into the back of the eye, which can be taxing on patients’ time and stress level. The new method utilizes a timed release capsule
read more »

April 2, 2017

Brain “rewires” itself to enhance other senses in blind people

Posted in: Latest News, Research and Developments

A common belief that blind people possess unusually heightened non-visual senses now may be more than just a belief. Credit: Bauer et al. PLOS ONE 2017 A new study led by Massachusetts Eye and Ear researchers has found that the brains of those who are born blind make new connections in the absence of visual information.
read more »

March 27, 2017

Once-Promising Study of Encapsulated Cell Technology Halted

Posted in: Latest News, Research and Developments

Researchers have found no significant difference between patients implanted with capsules manufacturing the drug NT-503 and patients receiving anti-VEGF drug injections. As reported on this site in 2015, Neurotech Pharmaceuticals, Inc. announced a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy (ECT) for the treatment of wet age-related macular degeneration (AMD). The study planned
read more »

March 17, 2017

Is Stem Cell Therapy Dangerous?

Posted in: Latest News, Research and Developments

Commentary by Dan Roberts, Editor Living Well With Low Vision The low vision community has been shaken this past week by news of three patients whose vision was damaged by stem cell treatment at a Florida clinic in 2015. There is good reason for concern, but not about the future of stem cell therapy for
read more »

March 13, 2017

OpRegen® for Dry-AMD in Trials

Posted in: Latest News, Research and Developments

BioTime, Inc. is expanding its ongoing Phase I/IIa clinical trial for OpRegen® for treatment of dry AMD. by naming the first two sites that will treat patients in the U.S. Adi Mohanty, Co-Chief Executive Officer of BioTime, said, “We are honored to be working with two of the leading U.S. clinicians in ophthalmology, Dr. David
read more »

March 8, 2017

Further Evidence of the Value of In-Home Occupational Therapy

Posted in: Latest News, Low Vision Rehabilitation, Research and Developments

A new study, published in the March 8 edition of Investigative Ophthalmology & Visual Science, has concluded that low-vision patients who improve in their daily living activities through at-home training with an occupational therapist (OT) have less severe symptoms of depression than similar patients who did not receive such training. Using outcomes from a recently
read more »

February 15, 2017

Another Anti-VEGF Drug Falls Short

Posted in: Latest News, Research and Developments

by Dan Roberts We announced here in December 2016 that Fovista, Ophthotech’s once-promising experimental drug for treatment of wet macular degeneration, failed to show positive results in Phase 3 trials, resulting in a discontinuance of the research. Now, Ohr Pharmaceuticals has announced temporary suspension of a clinical study for its drug candidate, Squalamine, an eye
read more »

Page 2 of 2012345...1020...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann